Literature DB >> 25093469

Risk of suicidal behavior with antidepressants in bipolar and unipolar disorders.

Andrew C Leon, Jess G Fiedorowicz, David A Solomon, Chunshan Li, William H Coryell, Jean Endicott, Jan Fawcett, Martin B Keller1.   

Abstract

OBJECTIVE: To examine the risk of suicidal behavior (suicide attempts and deaths) associated with antidepressants in participants with bipolar I, bipolar II, and unipolar major depressive disorders.
DESIGN: A 27-year longitudinal (1981-2008) observational study of mood disorders (Research Diagnostic Criteria diagnoses based on Schedule for Affective Disorders and Schizophrenia and review of medical records) was used to evaluate antidepressants and risk for suicidal behavior. Mixed-effects logistic regression models examined propensity for antidepressant exposure. Mixed-effects survival models that were matched on the propensity score examined exposure status as a risk factor for time until suicidal behavior.
SETTING: Five US academic medical centers.
RESULTS: Analyses of 206 participants with bipolar I disorder revealed 2,010 exposure intervals (980 exposed to antidepressants; 1,030 unexposed); 139 participants with bipolar II disorder had 1,407 exposure intervals (694 exposed; 713 unexposed); and 361 participants with unipolar depressive disorder had 2,745 exposure intervals (1,328 exposed; 1,417 unexposed). Propensity score analyses confirmed that more severely ill participants were more likely to initiate antidepressant treatment. In mixed-effects survival analyses, those with bipolar I disorder had a significant reduction in risk of suicidal behavior by 54% (HR = 0.46; 95% CI, 0.31-0.69; t = -3.74; P < .001) during periods of antidepressant exposure compared to propensity-matched unexposed intervals. Similarly, the risk was reduced by 35% (HR = 0.65; 95% CI, 0.43-0.99; t = -2.01; P = .045) in bipolar II disorder. By contrast, there was no evidence of an increased or decreased risk with antidepressant exposure in unipolar disorder.
CONCLUSIONS: Based on observational data adjusted for propensity to receive antidepressants, antidepressants may protect patients with bipolar disorders but not unipolar depressive disorder from suicidal behavior. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25093469      PMCID: PMC4142755          DOI: 10.4088/JCP.13m08744

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  35 in total

1.  Antidepressant use and risk for suicide attempts in bipolar disorder.

Authors:  Joseph F Goldberg
Journal:  J Clin Psychiatry       Date:  2011-12       Impact factor: 4.384

2.  Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.

Authors:  Robert D Gibbons; C Hendricks Brown; Kwan Hur; John Davis; J John Mann
Journal:  Arch Gen Psychiatry       Date:  2012-06

3.  A mixed-effects quintile-stratified propensity adjustment for effectiveness analyses of ordered categorical doses.

Authors:  Andrew C Leon; Donald Hedeker
Journal:  Stat Med       Date:  2005-02-28       Impact factor: 2.373

4.  Scientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology.

Authors:  G L Klerman
Journal:  Psychopharmacol Bull       Date:  1986

Review 5.  Can antidepressants cause mania and worsen the course of affective illness?

Authors:  T A Wehr; F K Goodwin
Journal:  Am J Psychiatry       Date:  1987-11       Impact factor: 18.112

6.  Insurance expenditures on bipolar disorder: clinical and parity implications.

Authors:  Pamela B Peele; Ying Xu; David J Kupfer
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

7.  Research diagnostic criteria: rationale and reliability.

Authors:  R L Spitzer; J Endicott; E Robins
Journal:  Arch Gen Psychiatry       Date:  1978-06

8.  The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.

Authors:  Isabella Pacchiarotti; David J Bond; Ross J Baldessarini; Willem A Nolen; Heinz Grunze; Rasmus W Licht; Robert M Post; Michael Berk; Guy M Goodwin; Gary S Sachs; Leonardo Tondo; Robert L Findling; Eric A Youngstrom; Mauricio Tohen; Juan Undurraga; Ana González-Pinto; Joseph F Goldberg; Ayşegül Yildiz; Lori L Altshuler; Joseph R Calabrese; Philip B Mitchell; Michael E Thase; Athanasios Koukopoulos; Francesc Colom; Mark A Frye; Gin S Malhi; Konstantinos N Fountoulakis; Gustavo Vázquez; Roy H Perlis; Terence A Ketter; Frederick Cassidy; Hagop Akiskal; Jean-Michel Azorin; Marc Valentí; Diego Hidalgo Mazzei; Beny Lafer; Tadafumi Kato; Lorenzo Mazzarini; Anabel Martínez-Aran; Gordon Parker; Daniel Souery; Ayşegül Ozerdem; Susan L McElroy; Paolo Girardi; Michael Bauer; Lakshmi N Yatham; Carlos A Zarate; Andrew A Nierenberg; Boris Birmaher; Shigenobu Kanba; Rif S El-Mallakh; Alessandro Serretti; Zoltan Rihmer; Allan H Young; Georgios D Kotzalidis; Glenda M MacQueen; Charles L Bowden; S Nassir Ghaemi; Carlos Lopez-Jaramillo; Janusz Rybakowski; Kyooseob Ha; Giulio Perugi; Siegfried Kasper; Jay D Amsterdam; Robert M Hirschfeld; Flávio Kapczinski; Eduard Vieta
Journal:  Am J Psychiatry       Date:  2013-11       Impact factor: 18.112

9.  The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies.

Authors:  M B Keller; P W Lavori; B Friedman; E Nielsen; J Endicott; P McDonald-Scott; N C Andreasen
Journal:  Arch Gen Psychiatry       Date:  1987-06

10.  Suicide attempts among patients starting depression treatment with medications or psychotherapy.

Authors:  Gregory E Simon; James Savarino
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

View more
  10 in total

1.  Mixed state and suicide: Is the effect of mixed state on suicidal behavior more than the sum of its parts?

Authors:  Jane E Persons; William H Coryell; David A Solomon; Martin B Keller; Jean Endicott; Jess G Fiedorowicz
Journal:  Bipolar Disord       Date:  2017-08-23       Impact factor: 6.744

Review 2.  Psychiatric Emergencies: Assessing and Managing Suicidal Ideation.

Authors:  Andrea N Weber; Maria Michail; Alex Thompson; Jess G Fiedorowicz
Journal:  Med Clin North Am       Date:  2017-03-08       Impact factor: 5.456

Review 3.  The influence of ketamine on drug discovery in depression.

Authors:  Christoph Kraus; Daniel Wasserman; Ioline D Henter; Elia Acevedo-Diaz; Bashkim Kadriu; Carlos A Zarate
Journal:  Drug Discov Today       Date:  2019-08-02       Impact factor: 7.851

Review 4.  Excess mortality in bipolar disorders.

Authors:  Christopher Miller; Mark S Bauer
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

Review 5.  Antidepressants and Mood Stabilizers: Novel Research Avenues and Clinical Insights for Bipolar Depression.

Authors:  In Hee Shim; Young Sup Woo; Moon-Doo Kim; Won-Myong Bahk
Journal:  Int J Mol Sci       Date:  2017-11-13       Impact factor: 5.923

6.  Interaction between Mesocortical and Mesothalamic Catecholaminergic Transmissions Associated with NMDA Receptor in the Locus Coeruleus.

Authors:  Motohiro Okada; Kouji Fukuyama
Journal:  Biomolecules       Date:  2020-07-01

7.  Lurasidone Sub-Chronically Activates Serotonergic Transmission via Desensitization of 5-HT1A and 5-HT7 Receptors in Dorsal Raphe Nucleus.

Authors:  Motohiro Okada; Kouji Fukuyama; Ruri Okubo; Takashi Shiroyama; Yuto Ueda
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-06

8.  Real-world clinical features of and antidepressant prescribing patterns for outpatients with bipolar disorder.

Authors:  Keita Tokumitsu; Norio Yasui-Furukori; Naoto Adachi; Yukihisa Kubota; Yoichiro Watanabe; Kazuhira Miki; Takaharu Azekawa; Koji Edagawa; Eiichi Katsumoto; Seiji Hongo; Eiichiro Goto; Hitoshi Ueda; Masaki Kato; Reiji Yoshimura; Atsuo Nakagawa; Toshiaki Kikuchi; Takashi Tsuboi; Kazutaka Shimoda; Koichiro Watanabe
Journal:  BMC Psychiatry       Date:  2020-11-23       Impact factor: 3.630

9.  Pharmacological Discrimination of Effects of MK801 on Thalamocortical, Mesothalamic, and Mesocortical Transmissions.

Authors:  Motohiro Okada; Kouji Fukuyama; Tomosuke Nakano; Yuto Ueda
Journal:  Biomolecules       Date:  2019-11-18

Review 10.  Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions.

Authors:  Motohiro Okada; Yasuhiro Kawano; Kouji Fukuyama; Eishi Motomura; Takashi Shiroyama
Journal:  Int J Mol Sci       Date:  2020-10-26       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.